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Abstract
Phosphorylation of receptor tyrosine kinases (RTKs) has a key role in cellular functions contributing to the malignant
phenotype of tumor cells. We and others have previously demonstrated that RTK ROR1 is overexpressed in chronic
lymphocytic leukemia (CLL). Silencing siRNA downregulated ROR1 and induced apoptosis of CLL cells. In the
present study we analysed ROR1 isoforms and the phosphorylation pattern in CLL cells (n=38) applying western blot
and flow-cytometry using anti-ROR1 antibodies and an anti-phospho-ROR1 antibody against the TK domain. Two
major ROR1 bands with the size of 105 and 130 kDa respectively were identified, presumably representing
unglycosylated (immature) and glycosylated (mature) ROR1 respectively as well as a 260 kDa band which may
represent dimerized ROR1. A ROR1 band of 64 kDa that may correspond to a C-terminal fragment was also noted,
present only in the nucleus. The 105 kDa ROR1 isoform was more frequently expressed in non-progressive as
compared to progressive CLL patients (p=0.03). The 64, 105, 130 and 260 kDa bands were constitutively
phosphorylated both at tyrosine and serine residues. Phosphorylation intensity of the mature (130 kDa) isoform was
significantly higher in progressive than in non-progressive disease (p<0.001). Incubation of CLL cells with a mouse
anti-ROR1 KNG or an anti-ROR1 CRD mAb respectively induced dephosphorylation of ROR1 before entering
apoptosis. In conclusion CLL cells expressed different isoforms of ROR1 which were constitutively phosphorylated.
The mature, phosphorylated ROR1 isoform was associated with a progressive disease stage. Targeting ROR1 by
mAbs induced specific dephosphorylation and leukemic cell death. ROR1 might be an interesting therapeutic target.
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Introduction
The receptor tyrosine kinase like orphan receptor 1 (ROR1)
belongs to one of the twenty receptor tyrosine kinase (RTK)
families and is evolutionarily highly conserved among different
species [1]. ROR1 is structurally related to other RTKs as the
Trk family and the muscle-specific kinase (MuSK). It is
expressed early during embryogenesis. The protein level peaks
at periods of active synapse formation, concentrated in the
growth cones of immature neurons and present throughout the
somatodendritic part of mature hippocampal cells [2].
The human ROR1 gene is located on chromosome 1
(1p31.3) (http://www.ensemble.org) with a coding region of
2814 bp and 937 amino acids (full length variant). The protein
consists of an extracellular part including 3 domains; the
immunoglobulin (Ig) like, the cysteine-rich (CRD) and the
kringle (KNG) domains as well as an intracellular tyrosine
kinase and a proline-rich domain. The ROR1 gene was
originally cloned from a neuroblastoma cell-line [1]. Wnt5a is a
ligand for ROR2 and activates canonical and non-canonical
pathways by binding to the frizzled 2 domain of ROR2 [3] and
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was also suggested to be a ligand for ROR1. However, other
Wnt proteins may also be considered [3].
Different isoforms of ROR1 has been reported (http://
www.ensembl.org) [4]. One of the isoforms is the full length
core protein, 937 aa (100-105 kDa unglycosylated)
(ROR1-001, ENSP00000360120). Another has a length of 393
aa (about 40 kDa) (ROR1-002, ENSP00000360121) and a
third of 388 aa (ROR1-201, ENSP00000441637). A truncated
ROR1 gene has been found in the fetal and adult human
central nervous system, in human leukemia and lymphoma
cell-lines and in a variety of human cancer derived from the
neuroectoderm with a predicted protein size of 40 kDa [4]. A 50
kDa ROR1 isoform has also been reported which may originate
from a splice variant [5].
We and others have demonstrated the overexpression of the
ROR1 protein in chronic lymphocytic leukemia (CLL) and other
lymphoid malignancies [5-7]. The expression was uniform [5,8]
and higher in progressive disease [8].
Post-translational modifications of proteins are important for
functional characteristics. Different ROR1 glycosylation
patterns have been reported in CLL. The fully glycosylated
isoform (130 kDa) has been suggested to be surface bound,
but it is unclear for the unglycosylated isoform (100-105 kDa)
[6,9]. Partially glycosylated isoforms have also been reported
[9].
Phosphorylation of RTKs, especially of tyrosine residues, is
an important mechanism for regulation of cellular functions
including cell division, protein synthesis and transcriptional
regulation. Phosphorylation at tyrosine or serine residues may
have various functional implications [10]. One third of all
cellular proteins and >95% of RTKs are phosphorylated at
tyrosine, serine and/or threonine residues [11]. Although
phosphorylation at tyrosine is less common (1.8%) than at
serine (86.4%) or threonine (11.8%) residues, tyrosine
phosphorylation is of significant importance in health and
disease [12].
In the present study, we analysed different ROR1 isoforms
and the phosphorylation status in CLL patients in various
clinical phases of the disease. We also evaluated the effects of
two apoptosis inducing anti-ROR1 mAbs (anti-KNG 4A7 and
anti-CRD 1D8) [8] on ROR1 phosphorylation. We
demonstrated that various ROR1 isoforms were differentially
expressed in non-progressive vs. progressive CLL patients and
ROR1 was constitutively phosphorylated particularly in
progressive CLL patients. Dephosphorylation of ROR1
preceded in vitro apoptosis induced by the anti-ROR1 mAbs.
Materials and Methods
Patients
Thirty eight CLL patients (21 with progressive and 17 with
non-progressive disease) were included in the study. The study
was approved by the Regional Ethics Committee (www.epn.se)
and signed written informed consent was obtained from each
patient prior to blood sampling. The diagnostic criteria for CLL
have been reported earlier [13]. Definition of non-progressive
(NP) and progressive (P) disease at the time of testing have
been described previously [13]. Peripheral blood mononuclear
cells (PBMC) and purified B-cells of healthy individuals were
used as controls.
Isolation of PBMC and B cells
PBMC were isolated using Ficoll-Hypaque (GE Healthcare,
Uppsala, Sweden) density-gradient centrifugation. B-cells from
healthy donors were isolated from PBMC using MACS negative
selection kits (Miltenyi Biotec, Bergisch Gladbach, Germany)
according to the manufacturer’s instructions as previously
described [14]. CD19 positive cells were enriched by negative
selection using MACS microbeads and midiMACS columns.
The purity of cells was >95% as determined by flow cytometry.
Flow cytometric surface and cytoplasmic staining
Surface staining of CLL cells was performed as described
[6,15]. Briefly, 106 cells were washed in PBS and suspended in
100 µl of FACS buffer (PBS with 0.1% sodium azide). A
polyclonal goat anti-ROR1 antibody (Ab) (3 µg) (against the
extracellular part of ROR1) (R&D system, Minneapolis, MN,
USA) and a goat IgG as a non-relevant isotype control Ab (3
µg) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were
added to the cells and incubated at 4 °C for 1 h before washing
twice with FACS buffer. The secondary antibody, FITC rabbit
anti-goat IgG (1:50) (Dako Cytomation, Glostrup, Denmark),
was added and incubated at 4 °C for 1 h, washed twice in
FACS buffer and fixed with 1% paraformaldehyde in PBS.
Intracytoplasmic staining of leukemic and normal PBMC was
performed as previously described [16]. A LSR II flow
cytometer (BD Biosciences, Mountain View, CA, USA) was
used and the data were analysed by FlowJo software program
(Tree Star Inc. Ashland, OR, USA).
Apoptosis assay
Apoptosis assay was done as previously described [8].
Briefly, 106 CLL cells were incubated with 10 µg/ml of two self-
produced anti-ROR1 monoclonal antibodies (mAbs) (against
the extracellular KNG and CRD domains of ROR1,
respectively) [8] or a non-relevant IgG1 isotype control mAb (10
ug/ml) or a human anti-CD20 Ab (ofatumumab) (10 ug/ml)
(GlaxoSmithKline, Research Triangle Park, NC, USA) in RPMI
1640 containing FCS. After 20 min, 1, 4, 12 and 18 h of
incubation at 37 °C, 105 cells were collected, washed twice in
PBS and resuspended in 100 ul of binding buffer. Five µl of
FITC-conjugated Annexin V and PI (BD Biosciences) was
added. The tubes were vortexed and incubated at room
temperature in the dark for 15 min. One hundred µl of binding
buffer was added to the cells which then were analyzed by flow
cytometry. Apoptotic/necrotic cells were determined as the
Annexin V+/PI+ population. Cell lysates were prepared and
stored at -20 °C for further analysis.
Immunoprecipitation of ROR1
Immunoprecipitation of ROR1 was done using a rat
monoclonal anti-human ROR1 antibody (against the
extracellular part of ROR1) (R&D). Briefly, 500 µg of cell lysate
was precleared with a mixture of protein G and protein A
agarose (Calbiochem, Darmstadt, Germany) at 4 °C for 2 h.
ROR1 Phosphorylation
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The supernatant was collected and incubated with protein G,
protein A agarose and 3 µg of the rat anti-human ROR1 mAb at
4 °C for overnight. Finally, precipitated agarose beads were
washed 3 times with lysis buffer and suspended in sample
buffer for further analysis by western blot.
Western blot analysis
PBMC from CLL patients or B-cells from healthy control
donors were lysed in buffer containing 150 mM NaCl, 25 mM
Tris-HCl, 1% NP-40, 1% Na deoxycholate, 0.1% sodium
dodecyl sulfate (SDS), 1% phosphatase inhibitor (Roche Ltd,
Basel, Switzerland) and 1% protease inhibitor cocktail (Sigma-
Aldrich Corp., Saint Louis, MO). Western blot was performed
as previously described [8]. Briefly, protein concentration of the
lysate was measured using BCA Protein Assay Kit according to
manufacturer’s instructions (Thermo Scientific, Barrington, IL,
USA). Twenty µg of cell lysate or immunoprecipitated ROR1
was run on 4-10% (gradient) or 10% Bis-Tris SDS-PAGE gels
(Invitrogen, Carlsbad, CA, USA) under non-reducing and
reducing (for immunoprecipitated ROR1) conditions. After
electrophoresis, resolved proteins were transferred to
Immobilon-PVDF membranes (Millipore Corporation, Bedford,
MA, USA) in a mini Transblot cell (Invitrogen). The membranes
were blocked at 4 °C with 5% non-fat milk or 5% BSA in TBS
containing 0.1% Tween 20 (TBS-T) overnight. Filters were
incubated with an anti-pROR1 mAb (against the intracellular
tyrosine kinase domain of ROR1) (a gift from Monoclonal
Antibody Research Center, Avicenna Research Institute,
Tehran, Iran), anti-phospho-tyrosine mAb (clone 4G10), anti-
phospho-serine mAb (clone 4A4) (Millipore) and a polyclonal
goat anti-human ROR1 Ab (R&D) for 2 h at room temperature.
Finally, peroxidase-conjugated rabbit anti-mouse or goat
immunoglobulins (Dako) were added for 1 h at room
temperature followed by extensive washing, before signals
were developed by Plus or Advanced ECL chemiluminescence
detection system (GE Healthcare) and a CCD camera (Fujifilm
LAS-4000).
Dephosphorylation experiments
The specificity of the anti-pROR1 mAb and
dephosphorylation of ROR1 in CLL cells was analysed using a
lambda protein phosphatase enzyme (New England BioLabs,
Hitchin, Hertfordshire, UK) which is a protein serine/threonine/
tyrosine phosphatase. Briefly, 40 µg protein lysate from CLL
cells without phosphatase inhibitor was incubated with 400
units of the phosphatase in the presence of protein metallo-
phosphatases and MnCl2 at 37 °C overnight. Treated and
untreated samples were analysed for ROR1 phosphorylation
using western blot.
pROR1 intensity measurement
Phosphorylation intensity of ROR1 bands (105, 130 and
105/130 kDa) in CLL cells were analysed by western blot
measuring the pROR1 intensity and the ROR1 (goat anti-
ROR1 pAb) intensity by the ImagJ1.44p software (National
Institute of Health, USA). The pROR1/ROR1 intensity ratio
after deduction of the background intensity was calculated.
Separation of nuclear and cytoplasmic proteins
Freshly prepared PBMCs of CLL patients were washed twice
in PBS before lysates were prepared using NE-PER®Nuclear
and cytoplasmic extraction reagents (Thermo Scientific),
according to manufacture’s instructions. To confirm that
proteins were localized to the correct fraction, western blot
analysis was performed using anti α/β-tubulin (Cell Signaling
Technology, Danvers, MA, USA), histone H3 and nucleolin
antibodies (Abcam, Cambridge, UK) before analysing the
expression pattern of ROR1 isoforms in the same preparation.
Statistical analysis
Statistical analyses were performed using the chi-square
test, independent sample T-test and Mann-Whitney U-test,
using the Epi-Info (Version 6, November 1993) and SPSS
statistical package (SPSS Inc., Chicago, IL, USA). The cut-off
for significance was set to p < 0.05.
Results
ROR1 isoforms in CLL cells
Cell lysates from CLL samples were immunoprecipitated
using a rat anti-ROR1 mAb. A polyclonal goat anti-human
ROR1 Ab was used for immunoblotting. A band of 105 kDa
was identified considered to represent the native
unglycosylated ROR1 as well as a 130 kDa band supposed to
represent the fully glycosylated monomer [5,6,9].
Representative blots are shown in Figures 1. Of these two
bands, one or the other seemed to dominate in individual
patients. A 260 kDa band was also noted, probably
representing dimerized ROR1 (homo or heterodimerization), as
the 260 kDa band was only noted under non-reducing
conditions. This is expected as disulfide bridges will be reduced
and dimers converted to monomers under reducing condition.
The expression of different ROR1 protein isoforms varied
between patients. The unglycosylated ROR1 isoform (105 kDa)
was more frequently seen in non-progressive (14 out of 17) as
compared to progressive (10 out of 21) patients (p=0.03).
Figure 1.  ROR1 isoforms in CLL.  Representative
experiments showing the presence of 260, 130 and 105 kDa
bands in CLL patients. P indicates progressive disease and NP
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Specificity of the anti-pROR1 mAb
A phosphatase enzyme removing all phosphate groups from
phosphorylated proteins was used to treat CLL lysates. A
representative experiment is shown in Figure 2. The anti-
pROR1 mAb detected a 130 kDa ROR1 band in samples not
treated with the enzyme, but a weak or no band in lysates
treated with the enzyme. The same blot was also probed with a
goat anti-ROR1 Ab. ROR1 band was detected in both
untreated and enzyme treated samples (Figure 2A).
Immunoprecipitated ROR1 (130 kDa) from CLL cells using a
goat anti-human ROR1 Ab could be detected by the anti-
pROR1 mAb (Figure 2B). The anti-pROR1 mAb was also
tested in ELISA, using a recombinant extracellular (KNG) part
of the ROR1 protein as well as in cell surface staining of CLL
cells. The pROR1 mAb did not react with the extracellular
ROR1 protein and did not stain the cell surface of CLL cells
(data not shown). The results suggest that our anti-pROR1
mAb reacts with a phosphorylated intracellular part of the
ROR1 molecule.
This antibody also detected a 64 kDa band (Figure 3A),
noted in 13/17 patients with non-progressive disease and 14/21
patients with progressive disease.
Phosphorylation of ROR1 in CLL cells
Phosphorylation of ROR1 in CLL cells was analysed using
cell lysates prepared from freshly isolated PBMC of 38 CLL
patients. ROR1 was constitutively phosphorylated in all
patients (Figure 3A). The 260, 130, 105 and 64 kDa isoforms
were phosphorylated both at tyrosine and serine residues. The
results could be confirmed by intracytoplasmic staining of CLL
cells using the anti-pROR1 mAb (Figure 3B).
Immunoprecipitation of CLL cell lysates using a non-relevant
IgG mAb did not show any bands. PBMC and normal B-cell
lysates from healthy donors using a rat anti-ROR1 mAb for IP
and probing with the anti-pROR1 mAb did not either reveal any
bands (data not shown).
The phosphorylation intensity of the 105 and 130 kDa bands
in progressive and non-progressive CLL patients was also
compared. There was no difference in the phosphorylation
intensity of the 105 kDa band comparing patients with
progressive and non-progressive disease at the time of testing.
However, the degree of phosphorylation of the 130 kDa band
was significantly higher in progressive than in non-progressive
Figure 2.  Specificity of anti-pROR1 antibody.  Western blot
analysis of CLL lysates from 3 CLL patients (5072, 5194, 5002)
treated with a lambda phosphatase enzyme. -: enzyme-
untreated sample, +: enzyme-treated sample. PVDF blot was
stripped and reprobed with a goat anti-ROR1 polyclonal Ab.
doi: 10.1371/journal.pone.0078339.g002
disease as was the case when measuring the intensity of both
isoforms together (Figure 4).
Cellular localization of ROR1 isoforms
The localization of the ROR1 isoforms in the cytoplasm and
nucleus respectively in leukemic cells was examined.
Antibodies against α/β-tubulin (a cytoplasmic protein), nucleolin
and histone H3 (nuclear proteins) were used to checked the
purity of the nucleus and cytoplasmic fraction of the leukemic
cells. Phosphorylated 105-130 kDa ROR1 isoforms were
localized both to the cytoplasm and nucleus. The
phosphorylated 64 kDa ROR1 isoform was only seen in the
nucleus. Results of 2 CLL patients and one healthy control are
shown in Figure 3C.
Anti-ROR1 mAb induced dephosphorylation of ROR1
We have previously shown that in vitro incubation of
leukemic cells with anti-ROR1 mAbs alone induced apoptosis
of CLL cells [8]. Here we examined ROR1 phosphorylation in
apoptotic CLL cells induced by our self-produced anti-ROR1
mAbs (KNG 4A7 and CRD 1D8) [8]. CLL cells from 5 (two
progressive and three non-progressive) patients were studied.
Representative experiments are shown in Figure 5, one for the
anti-KNG mAb (Figure 5A and C) and one for the anti-CRD
mAb (Figure 5B and D). Cell lysates were probed with the anti-
pROR1 Ab after 20 min, 1 h and 4 h of incubation with the
ROR1 monoclonal antibodies. Apoptosis/necrosis (Annexin V
+/PI+) was measured after 4 h, 12 h and 18 h of incubation.
Three CLL samples were exposed to the anti-KNG mAb and
two samples to the anti-CRD mAb. Dephosphorylation of the
130 kDa band was observed already after 20 min of incubation
with the anti-ROR1 mAbs (Figure 5A and B). Furthermore, a
weak dephosphorylation could also be noted for the 105 and
64 kDa bands respectively (data not shown). A non-relevant
isotype control mAb (IgG1) and the anti-CD20 mAb
(ofatumumab) did not induce dephosphorylation of ROR1
(Figure 5E). After 4 h of incubation with the anti-ROR1 mAbs,
only few cells entered apoptosis/necrosis (5-4%). At 12 and 18
h, 22-18% and 52-45%, respectively of leukemic cells were
apoptotic/necrotic (non-relevant IgG1 isotype control mAb: 19-7
% and 20-14%). The results suggest that dephosphorylation of
ROR1 was specific for both the anti-KNG (4A7) and anti-CRD
(1D8) mAbs and preceded apoptosis.
Discussion
Different isoforms of ROR1 (Table S1) could be shown to be
present in CLL cells. The most prominent bands were the 105
and 130 kDa isoforms which were localized both to the
cytoplasm and nucleus. We could also demonstrate the
presence of dimerized ROR1 (260 kDa). The other member of
the ROR family, ROR2 has been shown to be both
homodimerized [17,18] and heterodimerized [19].
Post-translational modifications of ROR1 might be of
functional significance. It was shown that ROR1 displayed a
non-unique glycosylation pattern in CLL [9], similar to our
findings. In ROR1, there are 7 potentially aspargine residues
for N-linked glycosylation and more that 24 serine and
ROR1 Phosphorylation
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Figure 3.  ROR1 isoforms and phosphorylation in CLL patients.  Representative experiments using non-immunoprecipitated
CLL cell lysates from 5 CLL patients showing phosphorylated dimerized ROR1 (260 kDa), fully glycosylated (130 kDa) and non-
glycosylated (105 kDa) ROR1 molecules (A). NP indicates non-progressive disease and P progressive disease. As controls, CLL
cell lysates immunoprecipitated with a non-relevant mAb (mouse IgG1 isotype) were used. No bands could be seen. Furthermore, in
PBMC of healthy donors, no bands were detected (data not shown). Representative experiments of PBMC using surface staining
for ROR1 (left panel) and intracytoplasmic staining for pROR1 (right panel) in three CLL patients (B). Expression of ROR1 isoforms
in the cytoplasm (C), nucleus (N) and total cell lysate (TCL) of leukemic CLL cells (C). Confirmation of protein localization was done
using antibodies against α/β –tubulin, histone H3 and nucleolin before analysing the expression pattern of ROR1.
doi: 10.1371/journal.pone.0078339.g003
ROR1 Phosphorylation
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threonine residues (http://www.cbs.dtu.dk/services) that might
be O-glycosylated contributing to a varying glycosylation
pattern. This may differ from patient to patient and between
cells of an individual CLL clone. In this study, as well as in our
previous report [6], we could show the presence of 100-130
kDa ROR1 glycoforms in CLL cells as has also been shown by
Kaucka et al [9]. Kaucka and co-workers demonstrated that
treatment of ROR1 transfected cells with tunicamycin (inhibiting
N-linked glycosylation) and brefeldin induced deglycosylation of
ROR1, yielding 100 and 115 kDa bands, while non-treated
cells expressed a 130 kDa ROR1 band. Before treatment of
CLL cells with N-glycosidase F, the 130 kDa ROR1 was the
most prominent glycoform and deglycosylation inhibited
surface expression of ROR1. Our present study confirms and
extends those results, showing different ROR1 isoforms in CLL
cells. The complete non-glycosylated (immature) ROR1 protein
(105 kDa) was more frequently expressed in patients with non-
progressive disease as compared to those with progressive
disease, indicating that glycosylation may relate to disease
activity as has been shown for other diseases [20].
A truncated ROR1 has been described in fetal CNS tissues,
adult human CNS tumors, leukemia/lymphoma cell lines and in
a variety of human cell lines of neuroectodermal origin using
northern blot analyses [4]. The truncated ROR1 contained 388
amino acids without posttranslational modifications
(approximately 40 kDa). This isoform was suggested to be
derived from alternative splicing [4] or a cleaved C-terminal
fragment (CTF) produced by surface proteolytic enzymes [21].
The size of this transcript (40 kDa) was different from what we
found (64 kDa).
The phosphorylated 64 kDa ROR1 isoform was only present
in the nucleus. The cytoplasmic domain of ROR1 has been
suggested to be a transcription factor but the target gene(s) are
not known [22]. The nuclear localized cytoplasmic domain of
ROR1 might play a role in cell migration and cytoskeleton
Figure 4.  Differential phosphorylation of ROR1 isoforms in
CLL in relation to disease activity.  pROR1/ROR1 intensity
(mean ± SEM) of the 105, 130 and combined 105+130 kDa
bands in progressive (■) (n=21) and non-progressive (☐) CLL
patients (n=17). *** p= 0.001.
doi: 10.1371/journal.pone.0078339.g004
remodeling, by upregulating genes involved in the regulation of
the actin cytoskeleton, including radixin (RDX), ezrin (EZR),
son of sevenless homolog 2 (SOS2) and caldesmon 1 (CALD1)
genes [23]. A similar phenomenon has been described for
other RTKs such as EGFR [24], ErbB2 [25], ErbB3 [26], ErbB4
[27] and VEGFR2 [28] where truncated versions had functional
implications for the growth of the tumor cells. In breast cancer
patients, a C-terminal fragment of HER2 (p95 HER2) lacking
the extracellular part has been shown to correlate with a poor
prognosis and resistance of HER2 positive cells to trastuzumab
therapy [29].
We could also demonstrate that the ROR1 isoforms were
constitutively phosphorylated at serine and tyrosine residues.
Covalent binding of phosphate groups to serine, threonine and
tyrosine residues are important for regulating protein activities
[30]. Constitutive phosphorylation including ligand-dependent
receptor dimerization/oligomerization of RTKs or ligand-
independent is of importance for cell signaling [31,32]. ErbB2
or HER2/neu, as well as ROR1 are members of the type I
RTKs contributing to the malignant phenotype of several
human cancers. High expression of HER1/2, VEGFR2/KRD as
well as estrogen receptors and their tyrosine phosphorylation in
breast cancer correlated to a poor prognosis [31,33-35]. Our
finding that phosphorylation of the mature ROR1 isoform (130
kDa) was significantly higher in progressive than in non-
progressive CLL patients is of interest. Furthermore, we have
also shown a significantly higher frequency of surface ROR1
expressing leukemic cells in progressive as compared to non-
progressive CLL patients [36]. Mature ROR1 might also to be
preferentially surface expressed [9]. Thus, there seems to be a
relation between ROR1 maturity, phosphorylation and disease
activity in CLL. Interestingly, induction of ROR1 expression in
TCL1 transgenic mice accelerated the development of CLL
[37].
It was recently shown that mouse ROR1 was phosphorylated
at serine position 652 [30] located in the activation segment of
ROR1, both in the human and mouse. This serine residue may
be an important site to be triggered by serine/threonine
kinases. The NetPhosK bioinformatic software (http://
www.cbs.dtu.dk/services/) for prediction of kinase specific
phosphorylation sites revealed that two tyrosine residues at
positions 641 and 646 of the intracytoplasmic part of ROR1
might have a high probability to be phosphorylated by tyrosine
kinases. There are three tyrosine residues which might be
potentially phosphorylated located at positions 186, 828 and
836 respectively. The peptide used for production of the anti-
phospho-ROR1 Ab was within the activation segment of the
two tyrosine and one serine residues.
It is not clear if constitutive phosphorylation of the ROR1
molecule at tyrosine [38-40] or serine [41,42] residues are due
to autophosphorylation or not. Constitutive tyrosine
phosphorylation triggered by other tyrosine kinases is a general
phenomenon observed for RTKs [43]. It was recently shown
that ROR1 had a low degree of autophosphorylation (low
catalytic activity), the same as for ErbB3, but not as strong as
for ErbB2 [44]. The Met oncogene has been suggested to
phosphorylate ROR1 at tyrosine residues as a consequence of
transphosphorylation [44]. The Met oncogene has also been
ROR1 Phosphorylation
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Figure 5.  Anti-ROR1 mAbs induced dephosphorylation of ROR1 and subsequent apoptosis of CLL cells.  Representative
experiments of time-dependent ROR1 dephosphorylation and apoptosis in vitro incubated with an anti-KNG (4A7) (A and C) and
anti-CRD (1D8) (B and D) anti-ROR1 mAb respectively. Representative experiments from two progressive (CLL 5102 and CLL
5116) CLL patients are shown. Leukemic cells were incubated for 20 min, 1, 4 hours with a non-relevant IgG1 isotype control mAb
(-) and the ROR1 mAbs (+). Cells were harvested and lysed for western blot experiments (A and B). The non-relevant isotype
control mAb did not induce dephosphorylation of ROR1 (130 kDa) while the anti-ROR1 mAb induced dephosphorylation already
after 20 min, which increased by time. The intensity of pROR1 was measured by ImageJ software. The ratio of pROR1/ROR1
intensity of treated sample to pROR1/ROR1 intensity of untreated sample (relative intensity) is shown in a histogram. A value <1
indicates dephosphorylation of ROR1 after treatment with the anti-ROR1 mAb compared to the non-relevant isotype control mAb.
Apoptosis of CLL cells (Annexin V+/PI+) after 0, 12 and 18 h incubation with the anti ROR1 mAbs without the addition of immune
effector cells or complement (C and D). An anti-CD20 mAb (ofatumumab) did not induce dephosphorylation of ROR1 after 4h
incubation in two CLL patients. A representative experiment is shown for one of the CLL patients (E).
doi: 10.1371/journal.pone.0078339.g005
ROR1 Phosphorylation
PLOS ONE | www.plosone.org 7 October 2013 | Volume 8 | Issue 10 | e78339
shown to be overexpressed in CLL cells but not in normal B
cells [45]. However, the Met oncogene is not the only kinase
that might phosphorylate ROR1, as a high level of ROR1
phosphorylation was observed in cell lines with normal Met
expression and activity [44]. Further studies are needed to
understand the mechanisms of ROR1 phosphorylation which
seems to be of importance for the malignant phenotype of
many tumor cells [44]. However, no mutational activations have
been shown for the ROR1 gene [6].
Binding of a ROR1 specific mAb to the external parts of the
receptor, both the KNG and CRD domains, was associated
with a rapid dephosphorylation of ROR1 preceding apoptosis of
CLL cells. Apoptosis occurred in the absence of immune
effector cells or complement. If ROR1 phosphorylation is ligand
independent, binding of a mAb to the extracellular part may
induce conformational changes and phospho-tyrosine residues
at the C-terminal may be triggered by phosphatases to
dephosphorylate ROR1, affecting ROR1 associated
downstream signaling pathways [38-40,42]. ROR1
phosphorylation might also be ligand dependent and binding of
the mAb may prevent binding of the ligand. Wnt5a has been
suggested to be a ligand of ROR1 [46] and CLL cells have
been shown to produce Wnt5a [47]. Further studies are needed
to clarify the mechanism of action of our anti-ROR1 specific
mAbs.
In summary, different ROR1 isoforms could be detected in
CLL cells, which were constitutively phosphorylated.
Phosphorylation was more pronounced in patients with
progressive than non-progressive disease. Anti-ROR1 mAbs
induced dephosphorylation of ROR1 in CLL cells preceding
apoptosis of the CLL cells. Further studies on the biology of
ROR1 in CLL and other malignancies are warranted to develop
ROR1 targeting therapeutics.
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